{"nctId":"NCT03338621","briefTitle":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","startDateStruct":{"date":"2018-07-30","type":"ACTUAL"},"conditions":["Tuberculosis, Pulmonary","Tuberculosis, Multidrug-Resistant","Tuberculosis, MDR","Tuberculosis","Drug-Resistant Tuberculosis"],"count":455,"armGroups":[{"label":"Drug Sensitive BPaMZ","type":"EXPERIMENTAL","interventionNames":["Drug: Pretomanid","Drug: Bedaquiline","Drug: Moxifloxacin","Drug: Pyrazinamide"]},{"label":"Drug Sensitive Standard Treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: HRZE","Drug: HR"]},{"label":"Drug Resistant BPaMZ","type":"EXPERIMENTAL","interventionNames":["Drug: Pretomanid","Drug: Bedaquiline","Drug: Moxifloxacin","Drug: Pyrazinamide"]}],"interventions":[{"name":"Pretomanid","otherNames":["PA-824","Pa"]},{"name":"Bedaquiline","otherNames":["B","TMC207"]},{"name":"Moxifloxacin","otherNames":["M"]},{"name":"Pyrazinamide","otherNames":["Z"]},{"name":"HRZE","otherNames":["isoniazid","rifampicin","ethambutol"]},{"name":"HR","otherNames":["isoniazid","rifampicin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \\[IUATLD\\]/WHO scale (Appendix 1) on smear microscopy) at the trial laboratory.\n* Participants with one of the following pulmonary TB conditions:\n\nDS-TB treatment arm participants should be:\n\n* sensitive to rifampicin and isoniazid by rapid sputum based test AND\n* either newly diagnosed for TB or have a history of being untreated for at least 3 years after cure from a previous episode of TB.\n\nDR-TB treatment arm participants should be Resistant to rifampicin and/or isoniazid.\n\n* Of non-childbearing potential or willing to practice effective methods of birth control\n* Body weight (in light clothing and no shoes) ≥ 30 kg.\n* Completed informed consent form\n\nExclusion Criteria:\n\n* Karnofsky score \\<60%\n* Any risk factor for QT prolongation\n* Any planned contraindicated medicines\n* Resistant to fluoroquinolones (rapid, sputum-based molecular screening tests).\n\nAny of the following lab toxicities/abnormalities:\n\n* CD4+ count \\< 100 cells/µL (HIV infected participants)\n* platelets \\<75,000/mm³\n* creatinine \\>1.5 times upper limit of normal (ULN)\n* eGFR ≤ 60 mL/min\n* haemoglobin \\<8.0 g/dL\n* serum potassium less than the lower limit of normal for the laboratory.\n* GGT: greater than 3 x ULN\n* AST: ≥3.0 x ULN to be excluded;\n* ALT: ≥3.0 x ULN to be excluded\n* ALP: ≥3.0 x ULN to be excluded\n* Total bilirubin: \\>1.5 x ULN to be excluded;\n* Direct bilirubin: greater than 1x ULN to be excluded","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Culture Negative Status by 8 Weeks","description":"Culture negative status is achieved when a participant produces at least two negative culture results at different visits (at least 7 days apart) without an intervening positive culture result for M.tb.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) at 52 Weeks From Start of Therapy (12 Months)","description":"Unfavorable status:\n\n1. Participants not classified as having achieved or maintained culture negative status when last seen\n2. Participants previously classified as having culture negative status who, following the end of treatment, have two positive cultures without an intervening negative culture\n3. Participants who had a positive culture not followed by at least two negative cultures when last seen\n4. Participants dying from any cause during treatment, except from violent or accidental cause, not including suicide\n5. Participants definitely or possibly dying from TB related cause during the follow-up phase\n6. Participants requiring an extension of their treatment beyond that permitted by the protocol a restart or a change of treatment for any reason except reinfection or pregnancy\n7. Participants lost to follow up or withdrawn from the study before end of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"134","spread":null},{"groupId":"OG002","value":"111","spread":null}]},{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Culture Negative Status","description":"Culture conversion is a diagnostic criteria indicating the point at which samples taken from a patient infected with a tuberculosis can no longer produce tuberculosis cell cultures, that point is considered culture negativity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":150},"commonTop":["Hyperuricaemia","Arthralgia","Hyperkalaemia","Nausea","Hepatic Enzyme Increased"]}}}